MILFORD, Pa., March 9, 2015 /PRNewswire/ -- Manzo
Pharmaceuticals, Inc. (OTCPink: MNZO), today announced its first
retail product, Tummy Relief™ is now carried at Esterbrook Pharmacy
in Reading, Pennsylvania, as the
start of a major push into brick and mortar retail.
Kenneth Manzo, The Company's CEO,
stated that he is actively promoting the product, and is continuing
the process of initiating talks with major retail chains to carry
the product nationwide. "It's time to start pushing forward with
the distribution of Tummy Relief™. As a Licensed Pharmacist, I feel
this is a superior product to anything on the market, and the time
has come to get it in the hands of consumers," said Mr. Manzo.
Another reason for Manzo to be excited is in regards to the
company's Lacto-Freedom™ product. The recent 6-month lab rat study
found that intestinal lactase levels were significantly higher in
the treated groups as compared to the untreated groups. The
3-month lactase levels were higher than the 6-month results showing
a decline in lactase production over time. At 3-months after
the probiotic was given, intestinal lactase levels increased 900%
with the lowest dose of Lacto-Freedom and 2400% with the highest
dose. At the 6-month mark, the lowest dose increased lactase
levels by 450% and the highest dose increased lactase levels by
1000%. In addition, there were no negative side effects even at
very high doses of Lacto-Freedom probiotic making the products
outlook extremely positive, and better than expected. Mr.
Manzo explains that the details that have been given so far have
been intentionally vague due to the fact that the company plans to
submit a new patent with the new data that was obtained during this
most recent six-month test. One of the strategies of the company is
to seek support from dairy product manufacturers, since if
Lacto-Freedom™ does what it has shown it is capable of so far in
the lab, it should create a huge increase in the demand for dairy
products benefitting manufacturers greatly.
Lastly, the company is happy to announce that it has recently
submitted a form1-a to the Securities and Exchange Commission as
part of a planned offering the company has put together with a
privately operated investment fund to raise capital. The fund
will be used to finance a human clinical study, and to repay
existing debt that was generated to pay for the recent six month
animal study as well as to cover the costs of running a publicly
traded company. The funds will also be used for continued
development and marketing of the Lacto-Freedom™ probiotic. The
company confirms that this is the reason for the recent increase in
authorized shares from 950 Million to 1.9 Billion, which it did
under advisement from William Eilers
of Eiler's Law, the firm handling the preparation and legal opinion
for the offering.
For more information listen to the CEO, Kenneth Manzo on the popular internet radio
show, The Stock Radio on Tuesday March
10th where he will be discussing the latest
developments.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical
company engaged in the research, development, and testing of
patented and non-patented solutions and remedies. Most notably is a
patented solution for lactose Intolerance, and a natural remedy for
colic in babies. For more information follow the company on twitter
at @manzopharma, and visit www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The Company has tried, whenever possible, to
identify these forward-looking statements using words such as
"anticipates," "believes," "estimates," "expects," "plans,"
"intends," "potential" and similar expressions. These statements
reflect the Company's current beliefs and are based upon
information currently available to it. Accordingly, such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance or achievements to differ materially
from those expressed in or implied by such statements. The Company
undertakes no obligation to update or advise in the event of any
change, addition or alteration to the information catered in this
Press Release including such forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-progress-as-retail-stores-start-to-carry-tummy-relief-300047106.html
SOURCE Manzo Pharmaceuticals, Inc.
